{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000049","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.853771+00:00","generated_at":"2026-06-17T10:28:31.466449+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou initiates dose expansion of CB-010 ANTLER trial in second-line LBCL patients","bullets":["CB-010 is first allogeneic CAR-T evaluated in second-line LBCL, per company.","Dose expansion will test 80x10^6 and 120x10^6 CAR-T cells in ~30 patients.","In dose escalation, no DLTs at dose level 3; at dose level 1, 6/6 complete response, 3/6 at 6 months, 2/6 at 12 months.","Company expects safety/efficacy update in H2 2023 with data from at least 15 dose-escalation patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000049","json":"https://secwatch.observer/filing/0001619856-23-000049.json","markdown":"https://secwatch.observer/filing/0001619856-23-000049.md","text":"https://secwatch.observer/filing/0001619856-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/0001619856-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/crbu-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:28:31.466449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}